#

Eli Lilly

: 92
Data on the subcutaneous form of Skyrizi likely drove the rise in AbbVies stock / Photo: ChrisStock82 / Shutterstock.com
News·
Pharmaceutical companies benefited from the sell-off in the AI sector. Which stocks are nearing their all-time highs?
The company plans to use the proceeds to advance its lead drug candidate, which is in early trials in patients with moderate or severe atopic dermatitis / Photo: Unsplash/Testalize.me
Small Caps·
+1
·
TRex Bio IPO: LLY-backed biotech focused on autoimmune, inflammatory diseases debuts
Oura pitched itself as a technology and data platform, but many investors saw it as a trendy wellness product / Photo: Erman Gunes / Shutterstock.com
News·
A single-product company: Lessons from Oura's stalled IPO
Viking has been developing its own candidate for obesity and type 2 diabetes, VK2735 / Photo: Shutterstock.com / Faizal Ramli
Small Caps·
+1
·
Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot
Novo Nordisk to Shorten Its Name to Compete with Eli Lilly / Photo: novonordisk.com
News·
Novo Nordisk will shorten its name and change its logo. Will this help revitalize the business?
Eli Lilly has once again expanded its portfolio of potential new drugs this year / Photo: Tada Images/Shutterstock.com
News·
Eli Lilly has found a new acquisition target. The company has already spent $20 billion this year
Eli Lilly Raises Forecast Thanks to the Success of Its Weight-Loss Drugs / Photo: Tada Image / Shutterstock.com
News·
Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline
Elon Musks SpaceX will release its first quarterly report this week following its IPO / Photo: X/SpaceX
News·
SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week
Profits at British pharmaceutical giant AstraZeneca exceeded analysts expectations last quarter. Photo: Konektus Photo/Shutterstock
News·
Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?
Novo Nordisk Accuses Eli Lilly of Unfair Advertising / Photo: oleschwander / Shutterstock
News·
Novo has filed a lawsuit against its competitor, Eli Lilly, over advertisements for weight-loss drugs
The transaction gives Eli Lilly access to AtaiBeckley’s experimental drug being studied in phase III clinical trials for treatment-resistant depression / Photo: Shutterstock.com / Tada Images
News·
+1
·
Eli Lilly officially to acquire psychedelics drugmaker AtaiBeckley for $3.8 bln
BlackRock warned clients against investing in Chinese indices / Photo: John Hanson Pye/Shutterstock.com
News·
BlackRock advised investors to focus on specific AI stocks in China rather than the entire region
Load more